Recent preclinical studies on dual targeting of acute myeloid leukemia with a transgenic NPM1-antigen-specific TCR and a CD33 CAR revealed that double transgenic receptor expression led to better cytotoxicity and tumor control relative to single receptor-expressing T cells (158). Here, NPM1 is linked to neoplasm.